Kristian Reich, Chief Scientific Officer, on July 15, 2026, sold 16,105 shares in Moonlake Immunotherapeutics (MLTX) for $322,261. Following the Form 4 filing with the SEC, Reich has control over a total of 2,843,835 Class A ordinary shares of the company, with 35,389 shares held directly and 2,808,446 controlled indirectly.
SEC Filing:
https://www.sec.gov/Archives/edgar/data/1821586/000121390026079376/xslF345X05/ownership.xml